Traditional approaches to biologics production—relying on one-size-fits-all expression vectors and empirical process optimization—have led to inefficiencies in expression, scalability, and ...

As demand for recombinant biologics and novel therapeutic modalities continues to grow, accelerating cell line development while maintaining high productivity is a critical challenge for ...

Successfully producing large quantities of biotherapeutics, including monoclonal antibodies and recombinant protein products, depends on robust and reliable cell line development (CLD). Issues that ...

Cell line creation is a major success factor in biologics manufacturing. It establishes the basis for product yield, quality, and long-term process stability. However, despite significant ...

How do you currently identify and select cells for further growth, characterization and processing? Many available cell-selection technologies lack the sensitivity necessary to preserve cell health ...